Semaglutide and gut microbiome changes — 16S rRNA sequencing data

Dr.KarenChen said:

Steady state is the thing most people miss.

Thank you for spelling out the reasoning rather than just the conclusion. Sending this to two other people who asked me the same thing last week.

Adding the clinical framing, because it changes how the question reads.

Dr.GutHealth said:

...but the FDA says semaglutide...

Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.

Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.

ingrid_STO said:

The mechanism that matters here is not stomach emptying, it is central.

Pushing back on ingrid_STO here. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

Adding the numbers, since they settle part of this. Worth stating the units and the reference range whenever you post a number here. A large fraction of the apparent disagreement in these threads is two people using different units and both being right.

Correct me if the detail matters more than I have assumed.

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Carry on.